Future therapy options for muscle-invasive bladder cancer

Future therapy options for muscle-invasive bladder cancer

VJOncology

1 year
60 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Treatment for muscle-invasive bladder cancer has evolved as medical knowledge has expanded. Jeanny Aragon-Ching, MD, FACP, from Inova Schar Cancer Institue, Falls Church, VA, explains how, previously, the single treatment for muscle-invasive bladder cancer was a radical cystectomy, where patients still did not have the best outcomes. She talks about the need to incorporate a multidisciplinary approach, including medical oncologists, surgeons and radiation oncologists, in order to reach the most suitable treatment choice. Dr Aragon-Ching stresses how finding the right biomarkers is necessary to deliver the best care. She highlights how immunotherapy treatments for muscle-invasive cancer are still experimental, yet are showing promising results. This interview was recorded at the Genitourinary Cancers Symposium 2018 in San Francisco, CA.
Up Next Autoplay
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
EV-103: Enfortumab Vedotin plus Pembrolizumab #ESMO19
Category: Bladder Cancer
13 Views
Cancer-News 1 month
EV-103 Phase I Trial Presented at #ESMO19
EV-103 Phase I Trial Presented at #ESMO19
Category: Bladder Cancer
21 Views
Cancer-News 1 month
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics and Astellas Announce US FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Category: Bladder Cancer
30 Views
Cancer-News 2 months
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
Category: Bladder Cancer
22 Views
Cancer-News 2 months
Strategies for Treating 2nd Line RCC Patients
Strategies for Treating 2nd Line RCC Patients
Category: Bladder Cancer
54 Views
obr 4 months
Treating Newly Diagnosed RCC Patients
Treating Newly Diagnosed RCC Patients
Category: Bladder Cancer
53 Views
obr 4 months
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Data on Enfortumab in Post-Platinum and I-O Bladder Cancer
Category: Bladder Cancer
110 Views
obr 4 months
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Combo Ipilimumab + Nivolumab in Histologies of Bladder Cancer
Category: Bladder Cancer
49 Views
obr 4 months
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
TROPHY-u-01 Trial: A Phase II Open-Label Study Of Sacituzumab Govitecan (IMMU-132) In Patients With Advanced Urothelial Cancer
Category: Bladder Cancer
175 Views
Annual-Meeting 5 months
The Broad Implications of The SAUL Study
The Broad Implications of The SAUL Study
Category: Bladder Cancer
208 Views
Annual-Meeting 5 months